Physician profile
Robert Remis
NPI 1528047974
$757.60
in general payments reported to CMS, 2019-2025
17 companies · $20.46 in 2025
The $20.46 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $128 · 2021: $61.39 · 2022: $17.11 · 2024: $141 · 2025: $20.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $161.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $190.33 | 2019-2022 | |
| Astellas Pharma US INC | $121.47 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $85.58 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $68.88 | 2024 | Strensiq |
| Mallinckrodt Hospital Products INC. | $36.23 | 2024 | Acthar |
| Amgen INC. | $36.23 | 2024 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $31.17 | 2019-2020 | |
| Antares Pharma, INC. | $26.81 | 2019 | |
| Pfizer INC. | $23.55 | 2019 | |
| Ucb, INC. | $20.46 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $20.34 | 2019 | |
| Boston Scientific Corporation | $19.64 | 2020 | |
| Neotract INC. | $18.20 | 2019 | |
| Abbvie INC. | $15.83 | 2019 | |
| Medtronic, INC. | $15.73 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $15.33 | 2019 | |
| Genzyme Corporation | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Remis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.